Fluoroquinolones Antibiotics May Increase the Risk of Heart Problems, Says Study

A new research study found that current users of fluoroquinolone antibiotics such as Cipro or Ciprofloxacin face 2.4 times greater risk of growing mitral and aortic regurgitation, where the blood flows back into the heart. It is compared to the people who take amoxicillin.

In this new study, the researchers have established a link between heart problems and antibiotic problems. Some physicians favor fluoroquinolone over antibiotics for their wide spectrum of high oral consumption and antibacterial activity. Fluoroquinolone is as effective as an intravenous treatment or IV treatment.

Mahyar Etminan, a lead author and a professor of visual science and ophthalmology at British Columbia University, said that patients can go home with an intake of one pill a day.

Etminan added that it is very convenient, but in many cases, particularly community-related infections, one day pill is not needed. Inappropriate medication may lead to serious heart problems and antibiotic resistance.

Dr. Bruce Carleton, director of the unit and research investigator at BC Children’s Hospital said that one of the major objectives of the therapeutic evaluation unit is to examine health technologies and drugs to determine whether they enhance the quality of care to improve patient outcomes.

The analysts have gathered the data from the U.S. Food and Drug Administration’s (FDA)  reporting system. They also examined the U.S. private healthcare insurance claims database, which captures the dose prescribed, demographics, treatment duration, and drug identification. The random sample collected by the researchers of more than nine million people found that there are more than twelve thousand cases of valvular regurgitation with 125,020 case-control subjects.

Researchers have defined a current exposure of fluoroquinolone as an active medication or prior 30 days to the adverse event, past exposure as within 61 to 365 days previous to an incident, recent exposure as within 31 to 60 days prior to an event. They have compared the use of fluoroquinolone with azithromycin and amoxicillin.

Analysts concluded that the risk of mitral and aortic regurgitation and the backflow blood into the heart is the highest with present use followed by recent use. With the past use, the researchers have not found any high risk associated with aortic and mitral regurgitation.